非小細胞肺癌一線免疫治療的成本效果

Lung cancer is the leading cause of cancer death, first-line immune checkpoint inhibitors have been reported to provide survival benefits compared with chemotherapy. However, the cost-effectivness should also be evaluated. This article reviewed 20 studies evaluating the cost-effectiveness of first-line immune checkpoint inhibitors for non-small cell lung cancer (NSCLC) between 2017 and 2020. These studies used clinical trial data, including KEYNOTE 024, KEYNOTE 042, KEYNOTE 189, KEYNOTE 407, CheckMate227, IMpower150, and IMpower130. Most of the cost-effectiveness studies appeared to show that first-line immune checkpoint inhibitors for NSCLC were not cost-effective. Constructing model for health technology assesment of lung cancer merits future research.